Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Introduction: recent advances in the understanding and management of multiple myeloma.

Jakubowiak AJ.

Semin Oncol. 2013 Oct;40(5):535-6. doi: 10.1053/j.seminoncol.2013.08.003. No abstract available.

PMID:
24135397
2.

Plasmacytoma of the skull.

Gozzetti A, Cerase A, Defina M, Bocchia M.

Eur J Haematol. 2012 Apr;88(4):369. doi: 10.1111/j.1600-0609.2011.01714.x. Epub 2011 Nov 15. No abstract available.

PMID:
22082085
3.

Multiple myeloma: epidemiology and therapeutic options.

Tuscano JM.

Manag Care. 2008 Jul;17(7 Suppl 6):9-15. Review.

4.

Advances in the treatment of multiple myeloma.

Dimopoulos MA, Terpos E.

Eur J Cancer. 2011 Sep;47 Suppl 3:S306-8. doi: 10.1016/S0959-8049(11)70181-2. No abstract available.

PMID:
21943993
5.

Treatment of multiple myeloma.

Clerc D, Fermand JP, Mariette X.

Joint Bone Spine. 2003 Jun;70(3):175-86. Review.

PMID:
12814760
6.

Clinical management of myeloma--state of the art.

Harousseau JL.

Cancer Treat Rev. 2010 May;36 Suppl 2:S1-2. doi: 10.1016/S0305-7372(10)00081-2.

PMID:
20472182
7.

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.

Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG.

Expert Rev Hematol. 2011 Feb;4(1):51-60. doi: 10.1586/ehm.10.83. Review.

PMID:
21322778
8.

Advances in the management of myeloma.

Hughes M, Soutar RL.

Scott Med J. 2005 May;50(2):47-50. Review. No abstract available.

PMID:
15977512
9.

Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.

Mangiacavalli S, Pica G, Varettoni M, Lazzarino M, Corso A.

Eur J Haematol. 2009 Mar;82(3):240-1. doi: 10.1111/j.1600-0609.2008.01184.x. Epub 2008 Nov 10. No abstract available.

PMID:
19018860
10.
11.
12.

Detection of Bence Jones myeloma and monitoring of myeloma chemotherapy using immunoassays specific for free immunoglobulin light chains.

Mead GP, Carr-Smith HD, Drayson MT, Bradwell AR.

Clin Lab. 2003;49(1-2):25-7. No abstract available.

PMID:
12593472
13.

Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents.

Nucci M, Anaissie E.

Clin Infect Dis. 2009 Oct 15;49(8):1211-25. doi: 10.1086/605664. Review.

PMID:
19769539
14.

Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma.

Amodio N, Di Martino MT, Neri A, Tagliaferri P, Tassone P.

Expert Opin Biol Ther. 2013 Jun;13 Suppl 1:S125-37. doi: 10.1517/14712598.2013.796356. Epub 2013 May 22. Review.

PMID:
23692413
15.
16.

Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors.

Allegra A, Sant'antonio E, Penna G, Alonci A, D'Angelo A, Russo S, Cannavò A, Gerace D, Musolino C.

Eur J Haematol. 2011 Feb;86(2):93-110. doi: 10.1111/j.1600-0609.2010.01558.x. Epub 2010 Dec 20. Review.

PMID:
21114539
17.

Novel agents and the paradigm of continuous treatment in multiple myeloma.

Palumbo A.

Leuk Res. 2012 Nov;36 Suppl 1:S1-2. doi: 10.1016/S0145-2126(12)00393-1. No abstract available.

PMID:
23176718
18.

Lenalidomide in multiple myeloma: current experimental and clinical data.

Cives M, Milano A, Dammacco F, Silvestris F.

Eur J Haematol. 2012 Apr;88(4):279-91. doi: 10.1111/j.1600-0609.2011.01735.x. Epub 2012 Jan 4. Review.

PMID:
22085323
19.

New horizons in multiple myeloma therapy.

Santos ES, Kharfan-Dabaja MA.

Expert Rev Anticancer Ther. 2006 Oct;6(10):1483-501. Review.

PMID:
17069532
20.

Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved?

El-Cheikh J, Crocchiolo R, Boher JM, Fürst S, Stoppa AM, Faucher C, Castagna L, Granata A, Oudin C, De Colella JM, Coso D, Bouabdallah R, Mohty M, Blaise D.

Leuk Lymphoma. 2012 Aug;53(8):1630-2. doi: 10.3109/10428194.2012.656630. Epub 2012 Feb 13. No abstract available.

PMID:
22239670

Supplemental Content

Support Center